CN112912066A - 一种尼莫地平注射液组合物及其制备方法 - Google Patents

一种尼莫地平注射液组合物及其制备方法 Download PDF

Info

Publication number
CN112912066A
CN112912066A CN201980063913.9A CN201980063913A CN112912066A CN 112912066 A CN112912066 A CN 112912066A CN 201980063913 A CN201980063913 A CN 201980063913A CN 112912066 A CN112912066 A CN 112912066A
Authority
CN
China
Prior art keywords
injection
nimodipine
composition
oil
emulsifier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980063913.9A
Other languages
English (en)
Other versions
CN112912066B (zh
Inventor
李宏
高山
毛黎静
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hainan Jiuxu Pharmaceutical Technology Co ltd
Jiangsu Jiuxu Pharmaceutical Co ltd
Li Hong
Original Assignee
Jiangsu Jiuxu Haitian Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Jiuxu Haitian Pharmaceutical Co ltd filed Critical Jiangsu Jiuxu Haitian Pharmaceutical Co ltd
Publication of CN112912066A publication Critical patent/CN112912066A/zh
Application granted granted Critical
Publication of CN112912066B publication Critical patent/CN112912066B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种尼莫地平注射液组合物及其制备方法。所述尼莫地平注射液组合物，以质量浓度计，包括如下组分：尼莫地平0.02‑0.23％，注射用油2‑30％，乳化剂0.8‑3％，络合剂0‑0.1％，稳定剂0‑0.3％，渗透压调节剂1‑3％。该组合物不含增溶剂乙醇，无吐温‑80等辅助乳化剂、苯甲醇等助溶剂。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN201980063913.9A 2018-09-08 2019-09-06 一种尼莫地平注射液组合物及其制备方法 Active CN112912066B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018110466294 2018-09-08
CN201811046629 2018-09-08
PCT/CN2019/104760 WO2020048533A1 (zh) 2018-09-08 2019-09-06 一种尼莫地平注射液组合物及其制备方法

Publications (2)

Publication Number Publication Date
CN112912066A true CN112912066A (zh) 2021-06-04
CN112912066B CN112912066B (zh) 2022-03-29

Family

ID=69721490

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980063913.9A Active CN112912066B (zh) 2018-09-08 2019-09-06 一种尼莫地平注射液组合物及其制备方法

Country Status (5)

Country Link
US (1) US20210338649A1 (zh)
EP (1) EP3848021A4 (zh)
JP (1) JP2021535932A (zh)
CN (1) CN112912066B (zh)
WO (1) WO2020048533A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116754711A (zh) * 2023-08-17 2023-09-15 蓝星安迪苏南京有限公司 饲料用乳化剂的乳化能力评估方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114557960A (zh) * 2022-03-16 2022-05-31 陕西省人民医院 一种治疗蛛网膜下腔出血的药物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101416942A (zh) * 2008-12-02 2009-04-29 沈阳万爱普利德医药科技有限公司 尼莫地平亚微乳注射液及其制备方法
CN101797226A (zh) * 2009-02-10 2010-08-11 上海医药工业研究院 一种高抗氧化性中/长链脂肪乳注射液及其制备方法
CN103893119A (zh) * 2014-03-07 2014-07-02 广东药学院 一种尼莫地平的脂肪乳注射液及其制备方法
US20170296527A1 (en) * 2016-04-13 2017-10-19 Grace Therapeutics Llc Stable nimodipine parenteral formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100386078C (zh) * 2004-07-08 2008-05-07 上海医药工业研究院 尼莫地平乳注射液及制备方法
CN101199522A (zh) * 2006-12-15 2008-06-18 重庆药友制药有限责任公司 注射用尼莫地平冻干乳剂及其制备方法
CN101904814A (zh) * 2009-06-04 2010-12-08 上海恒瑞医药有限公司 制备载药乳剂的方法
US9399019B2 (en) * 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
CN107661294B (zh) * 2016-07-27 2020-04-14 武汉科福新药有限责任公司 抗高血压药物脂肪乳注射剂及其制备方法
US20180098977A1 (en) * 2016-08-23 2018-04-12 Edge Therapeutics, Inc. Scalable microparticulate formulations containing polymorphic nimodipine form 2 prepared by a solvent evaporation process

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101416942A (zh) * 2008-12-02 2009-04-29 沈阳万爱普利德医药科技有限公司 尼莫地平亚微乳注射液及其制备方法
CN101797226A (zh) * 2009-02-10 2010-08-11 上海医药工业研究院 一种高抗氧化性中/长链脂肪乳注射液及其制备方法
CN103893119A (zh) * 2014-03-07 2014-07-02 广东药学院 一种尼莫地平的脂肪乳注射液及其制备方法
US20170296527A1 (en) * 2016-04-13 2017-10-19 Grace Therapeutics Llc Stable nimodipine parenteral formulation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116754711A (zh) * 2023-08-17 2023-09-15 蓝星安迪苏南京有限公司 饲料用乳化剂的乳化能力评估方法
CN116754711B (zh) * 2023-08-17 2023-11-07 蓝星安迪苏南京有限公司 饲料用乳化剂的乳化能力评估方法

Also Published As

Publication number Publication date
EP3848021A1 (en) 2021-07-14
US20210338649A1 (en) 2021-11-04
WO2020048533A1 (zh) 2020-03-12
CN112912066B (zh) 2022-03-29
JP2021535932A (ja) 2021-12-23
EP3848021A4 (en) 2023-11-29

Similar Documents

Publication Publication Date Title
JP7048576B2 (ja) 酸素化コレステロールサルフェート、並びにポリアルキレングリコール、カルボキシメチルセルロース、及びポリオキシルグリセリドのうち少なくとも１種を含む組成物
JP5847722B2 (ja) ｐＨ調節剤を含むタキサンの医薬溶液、およびその作製方法
CN112912066B (zh) 一种尼莫地平注射液组合物及其制备方法
CN109922794A (zh) 使用脂质体构建体将尿素递送至黄斑和视网膜的细胞
CN1985851B (zh) 含有蟾酥提取物的脂质微球注射液及其制备方法
EP2813215A1 (en) 2,2',6,6'-tetraisopropyl-4,4'-2-biphenol lipid microsphere preparation and preparation method therefor
CN100515389C (zh) 一种适用于难溶性药物的药用乳剂及其制备方法
CN106137963B (zh) 抗心律失常药物脂肪乳注射液及其制备方法
KR20130062282A (ko) 진정 수면제의 주사가능한 에멀젼
RU2504347C1 (ru) Инъекционная лекарственная форма для лечения и профилактики заболеваний печени у животных
KR102256847B1 (ko) 체중-증량 화합물의 장기 사용을 위한 조성물 및 방법
CN108853056A (zh) 一种叶酸靶向修饰共载盐酸阿霉素和藤黄酸纳米结构脂质载体制剂及其制备方法
CN115517984A (zh) 氧气缓释型纳米乳液组合物以及其制备方法
CN109260149B (zh) 一种含有γ-生育三烯酚的纳米乳液及其制备方法和用途
CN1965805A (zh) 辅酶q10亚微乳注射液及制备方法
CN105935443A (zh) 一种治疗糖尿病性白内障的药物组合物
CN104771360A (zh) 一种蒿甲醚纳米乳药物组合物及其制备方法
WO2024032050A1 (zh) 可自乳化的多西他赛注射用组合物及其制备方法
CN102793730B (zh) 银杏达莫的药物组合物及其制备方法
WO2024056028A1 (en) Analgesic polypeptide
CN103405396B (zh) 一种含蓬莪术环二烯的药物组合物及其制药用途
KR102619489B1 (ko) 폴마콕시브 및 트라마돌을 포함하는 급, 만성 통증 치료용 약제학적 조성물
RU2676279C1 (ru) Стабильное противоопухолевое лекарственное средство, способ его получения и применения
CN107106649A (zh) 含脱辅基水母发光蛋白的组合物及其用于治疗神经元炎症的方法
ZARĘBSKA et al. Histological changes in the retina in experimental alloxan-induced diabetes in rabbits

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220217

Address after: 221200 No. 998, Jiuxu Avenue, Suining County, Xuzhou City, Jiangsu Province

Applicant after: JIANGSU JIUXU PHARMACEUTICAL Co.,Ltd.

Applicant after: Li Hong

Address before: 221200 No. 998, Jiuxu Avenue, Suining Economic Development Zone, Xuzhou City, Jiangsu Province

Applicant before: Jiangsu Jiuxu Haitian Pharmaceutical Co.,Ltd.

Applicant before: Li Hong

CB02 Change of applicant information

Address after: 221200 No. 998, Jiuxu Avenue, Suining Economic Development Zone, Xuzhou City, Jiangsu Province

Applicant after: JIANGSU JIUXU PHARMACEUTICAL Co.,Ltd.

Applicant after: Li Hong

Address before: 221200 Xuzhou City, Jiangsu Province, China Xuzhou City, Jiangsu Province, Suining County, Jiuxu Avenue, No. 998

Applicant before: JIANGSU JIUXU PHARMACEUTICAL Co.,Ltd.

Applicant before: Li Hong

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220929

Address after: 221200 No. 998, Jiuxu Avenue, Suining Economic Development Zone, Xuzhou City, Jiangsu Province

Patentee after: Li Hong

Patentee after: JIANGSU JIUXU PHARMACEUTICAL Co.,Ltd.

Patentee after: Hainan Xinglin Pharmaceutical Technology Co.,Ltd.

Address before: 221200 No. 998, Jiuxu Avenue, Suining Economic Development Zone, Xuzhou City, Jiangsu Province

Patentee before: JIANGSU JIUXU PHARMACEUTICAL Co.,Ltd.

Patentee before: Li Hong

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 221200 No. 998, Jiuxu Avenue, Suining Economic Development Zone, Xuzhou City, Jiangsu Province

Patentee after: Li Hong

Country or region after: China

Patentee after: JIANGSU JIUXU PHARMACEUTICAL Co.,Ltd.

Patentee after: Hainan Jiuxu Pharmaceutical Technology Co.,Ltd.

Address before: 221200 No. 998, Jiuxu Avenue, Suining Economic Development Zone, Xuzhou City, Jiangsu Province

Patentee before: Li Hong

Country or region before: China

Patentee before: JIANGSU JIUXU PHARMACEUTICAL Co.,Ltd.

Patentee before: Hainan Xinglin Pharmaceutical Technology Co.,Ltd.